Oc­u­lar Ther­a­peu­tix's last-minute gam­bit fails to sal­vage its sec­ond FDA ap­pli­ca­tion, shares plunge

An 11th hour bid by Oc­u­lar Ther­a­peu­tix to sal­vage its FDA ap­pli­ca­tion for their drug/de­vice eye treat­ment Dex­ten­za got shot down in a hur­ry on Tues­day.

A year af­ter Oc­u­lar re­ceived its first re­jec­tion of the eye ther­a­py based on man­u­fac­tur­ing is­sues, the Bed­ford, MA-based com­pa­ny was hand­ed its sec­ond com­plete re­sponse let­ter af­ter in­spec­tors flagged is­sues dur­ing a pre-NDA in­spec­tion a cou­ple of months ago.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.